Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bronchiolitis Obliterans Syndrome: early-phase trial registry
3 of 6 indexed Bronchiolitis Obliterans Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Bronchiolitis Obliterans Syndrome: 6 US clinical trials tracked, 3 recruiting.
Bronchiolitis Obliterans Syndrome is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Zambon SpA, running 1 of these trials.
Enrollment posture brief
Registry condition bronchiolitis-obliterans-syndrome
OPEN 3 | RECR 50% | LATE 1 | EARLY 3 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Bronchiolitis Obliterans Syndrome lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bronchiolitis Obliterans Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bronchiolitis Obliterans Syndrome is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Bronchiolitis Obliterans Syndrome research.
Zambon SpA accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Bronchiolitis Obliterans Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Bronchiolitis Obliterans Syndrome splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Fred Hutchinson Cancer Center
NCT05250037
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Dana-Farber Cancer Institute
NCT05922761
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Steven Hays, MD
NCT06018766
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
Zambon SpA
NCT04039347
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)
NCT02669251
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation
University of Chicago
NCT00528853
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Bronchiolitis Obliterans Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bronchiolitis Obliterans Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bronchiolitis Obliterans Syndrome page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Bronchiolitis Obliterans Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zambon SpA sponsors the most Bronchiolitis Obliterans Syndrome trials on record, review their full trial history before evaluating a specific study. See Zambon SpA's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bronchiolitis Obliterans Syndrome condition card totals 6 registered trials; most-linked intervention Liposomal Cyclosporine A 10 mg; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.